A Phase 3 interventional study of Ibrutinib in Graft vs Host Disease, sponsored by Janssen Pharmaceutical K.K.. Completed at 15 sites in Japan. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-02-04.
Sponsored by Janssen Pharmaceutical K.K. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Graft vs Host Disease with a site in Japan — 1 open to participants now, 2 under way, none of them phase 3. Graft vs Host Disease · Japan.
Among the 13 studies in Graft vs Host Disease with a site in Japan, this one is one of 2 that started in 2018, is one of 4 in phase 3, and was the 8th registered.
804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.
Browse Graft vs Host Disease studies →1 of the 13 studies in Graft vs Host Disease with a site in Japan is open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Japan
Ages 0+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 5 · Phase 4 1
First in 2004; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 19 is below the median of 35 across 639 interventional studies indexed under Graft vs Host Disease.
Median enrollment 193 across the 9 interventional studies, 348 across the 2 observational. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 13 have an industry lead sponsor. The 7 most frequent:
This study is registered under Janssen Pharmaceutical K.K., one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Pharmaceutical K.K. is the lead sponsor of 126 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 7 (50%) have results posted.
Johnson & Johnson has 1 study filed under Graft vs Host Disease — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Graft vs Host Disease with a site in Japan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate efficacy of ibrutinib in Japanese participants with steroid dependent/refractory chronic graft versus host disease (cGVHD) by measuring overall cGVHD response (complete response [CR] and partial response [PR] defined by National Institutes of Health [NIH] consensus development project criteria [2014]).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 420 milligram (mg) oral ibrutinib once daily starting on Week 1 Day 1, unless they have intervening unacceptable toxicity or meet other criteria for participants discontinuation.
Drug: Ibrutinib
Participants will receive 420 mg (3 \* 140 mg capsules) oral ibrutinib once daily starting on Week 1 Day 1, unless they have intervening unacceptable toxicity or meet other criteria for participants discontinuation.
Also known as: PCI-32765, JNJ-54179060
Overall Response Rate (ORR)
ORR is defined as the percentage of participants who achieve complete response (CR) or partial response (PR) in the absence of new therapy for chronic graft versus host disease (cGVHD) and absence of progression of underlying disease or death based on the National Institutes of Health (NIH) Consensus Development Project Criteria (2014). CR is defined as resolution of all manifestations in each organ or site; PR is defined as improvement in at least 1 organ or site without progression in any other organ or site; and chronic graft versus host disease (cGVHD) progression is defined as clinically meaningful worsening in 1 or more organs regardless of improvement in other organs.
Time frame: Up to 3 year 6 months
Sustained Response Rate
Sustained response rate was defined as percentage of participants with NIH defined CR or PR that was sustained for at least 20 weeks. CR is defined as resolution of all manifestations in each organ or site; PR is defined as improvement in at least 1 organ or site without progression in any other organ or site.
Time frame: Up to 3 year 6 months
Duration of Response (DOR)
DOR is defined as the duration from the date of initial response (CR or PR) to the date of progressive cGVHD or death, whichever occurred first. CR is defined as resolution of all manifestations in each organ or site; PR is defined as improvement in at least 1 organ or site without progression in any other organ or site; and cGVHD progression is defined as clinically meaningful worsening in 1 or more organs regardless of improvement in other organs.
Time frame: Up to 3 year 6 months
cGVHD Response Rate at Each Timepoints
cGVHD response rate was defined as percentage of participants with NIH defined CR or PR at each timepoint. CR is defined as resolution of all manifestations in each organ or site; PR is defined as improvement in at least 1 organ or site without progression in any other organ or site.
Time frame: Weeks 5, 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157
Change in the Amount of Corticosteroid Required Over Time
Change in the amount of corticosteroid required over time was reported.
Time frame: Baseline, Weeks 24, 48, 96, and 144
Percentage of Participants With Overall Improvement in Lee cGVHD Symptom Scale Score
Percentage of participants with overall improvement in Lee cGVHD symptom scale score was reported. Lee cGVHD symptom scale is a patient-reported symptom scale used to measure symptom burden and has 7 subscales (Skin, Eyes and Mouth, Breathing, Eating and Digestion, Muscles and Joints, Energy, and Mental and Emotional) with ratings as follows: 0-Not at all, 1-Slightly, 2-Moderately, 3-Quite a bit, 4-Extremely, with lower values representing a better outcome. A score was calculated for each subscale by taking the mean of all items completed if more than 50% were answered and normalizing to a 0 to 100 with a higher score indicating worse symptoms. An overall score was calculated as the average of these 7 subscales if at least 4 subscales had valid scores. A change of greater than or equal to (\>=) 7 points on the Lee cGVHD symptom scale overall score was considered significant and relates to improvement in quality of life (QoL).
Time frame: Up to 3 year 6 months
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs are adverse events with onset during the treatment phase or that were a consequence of a preexisting condition that has worsened since baseline, and occurred during treatment or within 30 days following the last dose of study treatment, or any adverse event that was considered study treatment-related regardless of the start date of the event.
Time frame: Up to 3 year 6 months
Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Measurable Concentration (AUC [0-last]) of Ibrutinib
AUC(0-last) is defined as area under the plasma concentration-time curve from time zero to time of last measurable concentration of ibrutinib.
Time frame: Day 1 of Weeks 1 and 2
Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours (AUC [0-24]) of Ibrutinib
AUC(0-24) is defined as area under the plasma concentration-time curve from time zero to 24 hours of ibrutinib.
Time frame: 0 to 24 hours (Day 1 of Weeks 1 and 2)
Maximum Observed Plasma Concentration (Cmax) of Ibrutinib
Cmax is defined as maximum observed plasma concentration of ibrutinib.
Time frame: Day 1 of Weeks 1 and 2
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Ibrutinib
Tmax is defined as time to reach the maximum observed plasma concentration of ibrutinib.
Time frame: Day 1 of Weeks 1 and 2
Elimination Half-Life (t1/2) of Ibrutinib
T1/2 is defined as elimination half-life of ibrutinib.
Time frame: Day 1 of Weeks 1 and 2
Apparent Clearance (CL/F) of Ibrutinib
CL/F is defined as apparent clearance of ibrutinib.
Time frame: Day 1 of Weeks 1 and 2
Apparent Volume of Distribution (Vd/F) of Ibrutinib
Vd/F is defined as apparent volume of distribution of ibrutinib.
Time frame: Day 1 of Weeks 1 and 2
Area Under the Plasma Concentration-time Curve From Time Zero to Infinite Time (AUC[0-infinity]) of Ibrutinib
AUC(0-infinity) is defined as area under the plasma concentration-time curve from time zero to infinite time of ibrutinib.
Time frame: Day 1 of Weeks 1 and 2
Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Measurable Concentration (AUC [0-last]) of PCI-45227
AUC(0-last) is defined as area under the plasma concentration-time curve from time zero to time of last measurable concentration of PCI-45227.
Time frame: Day 1 of Weeks 1 and 2
Area Under the Plasma Concentration-Time Curve From Time Zero to 24 Hours (AUC [0-24]) of PCI-45227
AUC(0-24) is defined as area under the plasma concentration-time curve from time zero to 24 hours of PCI-45227.
Time frame: 0 to 24 hours (Day 1 of Weeks 1 and 2)
Maximum Observed Plasma Concentration (Cmax) of PCI-45227
Cmax is defined as maximum observed plasma concentration of PCI-45227.
Time frame: Day 1 of Weeks 1 and 2
Time to Reach Maximum Observed Plasma Concentration (Tmax) of PCI-45227
Tmax is defined as time to reach the maximum observed plasma concentration of PCI-45227.
Time frame: Day 1 of Weeks 1 and 2
Elimination Half-Life (t1/2) of PCI-45227
T1/2 is defined as elimination half-life of PCI-45227.
Time frame: Day 1 of Weeks 1 and 2
Apparent Clearance (CL/F) of PCI-45227
CL/F is defined as apparent clearance of PCI-45227.
Time frame: Day 1 of Weeks 1 and 2
Apparent Volume of Distribution (Vd/F) of PCI-45227
Vd/F is defined as apparent volume of distribution of PCI-45227.
Time frame: Day 1 of Weeks 1 and 2
Area Under the Plasma Concentration-time Curve From Time Zero to Infinite Time (AUC[0-infinity]) of PCI-45227
AUC(0-infinity) is defined as area under the plasma concentration-time curve from time zero to infinite time of PCI-45227.
Time frame: Day 1 of Weeks 1 and 2
| Milestone | Ibrutinib 420 mg |
|---|---|
| Started | 19 |
| Completed | 11 |
| Not completed | 8 |
| Withdrew: Death | 7 |
| Withdrew: Withdrawal by subject | 1 |
ORR is defined as the percentage of participants who achieve complete response (CR) or partial response (PR) in the absence of new therapy for chronic graft versus host disease (cGVHD) and absence of progression of underlying disease or death based on the National Institutes of Health (NIH) Consensus Development Project Criteria (2014). CR is defined as resolution of all manifestations in each organ or site; PR is defined as improvement in at least 1 organ or site without progression in any other organ or site; and chronic graft versus host disease (cGVHD) progression is defined as clinically meaningful worsening in 1 or more organs regardless of improvement in other organs.
| Percentage of participants | Ibrutinib 420 mg |
|---|---|
| Overall Response Rate (ORR) | 84.2 |
Sustained response rate was defined as percentage of participants with NIH defined CR or PR that was sustained for at least 20 weeks. CR is defined as resolution of all manifestations in each organ or site; PR is defined as improvement in at least 1 organ or site without progression in any other organ or site.
| Percentage of participants | Ibrutinib 420 mg |
|---|---|
| Sustained Response Rate | 68.8 |
DOR is defined as the duration from the date of initial response (CR or PR) to the date of progressive cGVHD or death, whichever occurred first. CR is defined as resolution of all manifestations in each organ or site; PR is defined as improvement in at least 1 organ or site without progression in any other organ or site; and cGVHD progression is defined as clinically meaningful worsening in 1 or more organs regardless of improvement in other organs.
| Months | Ibrutinib 420 mg |
|---|---|
| Duration of Response (DOR) | NA (5.30 to NA) |
cGVHD response rate was defined as percentage of participants with NIH defined CR or PR at each timepoint. CR is defined as resolution of all manifestations in each organ or site; PR is defined as improvement in at least 1 organ or site without progression in any other organ or site.
| Percentage of participants | Ibrutinib 420 mg |
|---|---|
| Week 5 | 26.3 (9.1 to 51.2) |
| Week 13 | 42.1 (20.3 to 66.5) |
| Week 25 | 52.6 (28.9 to 75.6) |
| Week 37 | 47.4 (24.4 to 71.1) |
| Week 49 | 47.4 (24.4 to 71.1) |
| Week 61 | 42.1 (20.3 to 66.5) |
| Week 73 | 36.8 (16.3 to 61.6) |
| Week 85 | 31.6 (12.6 to 56.6) |
| Week 97 | 31.6 (12.6 to 56.6) |
| Week 109 | 31.6 (12.6 to 56.6) |
| Week 121 | 36.8 (16.3 to 61.6) |
| Week 133 | 31.6 (12.6 to 56.6) |
| Week 145 | 26.3 (9.1 to 51.2) |
| Week 157 | 10.5 (1.3 to 33.1) |
Change in the amount of corticosteroid required over time was reported.
| Milligrams per kilograms per day | Ibrutinib 420 mg |
|---|---|
| Baseline | 0.270 (0.08 to 1.77) |
| Week 24 | 0.250 (0.08 to 0.87) |
| Week 48 | 0.150 (0.06 to 0.64) |
| Week 96 | 0.140 (0.01 to 0.59) |
| Week 144 | 0.140 (0.05 to 0.56) |
Percentage of participants with overall improvement in Lee cGVHD symptom scale score was reported. Lee cGVHD symptom scale is a patient-reported symptom scale used to measure symptom burden and has 7 subscales (Skin, Eyes and Mouth, Breathing, Eating and Digestion, Muscles and Joints, Energy, and Mental and Emotional) with ratings as follows: 0-Not at all, 1-Slightly, 2-Moderately, 3-Quite a bit, 4-Extremely, with lower values representing a better outcome. A score was calculated for each subscale by taking the mean of all items completed if more than 50% were answered and normalizing to a 0 to 100 with a higher score indicating worse symptoms. An overall score was calculated as the average of these 7 subscales if at least 4 subscales had valid scores. A change of greater than or equal to (\>=) 7 points on the Lee cGVHD symptom scale overall score was considered significant and relates to improvement in quality of life (QoL).
| Percentage of participants | Ibrutinib 420 mg |
|---|---|
| Percentage of Participants With Overall Improvement in Lee cGVHD Symptom Scale Score | 52.6 (28.9 to 75.6) |
An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs are adverse events with onset during the treatment phase or that were a consequence of a preexisting condition that has worsened since baseline, and occurred during treatment or within 30 days following the last dose of study treatment, or any adverse event that was considered study treatment-related regardless of the start date of the event.
| Participants | Ibrutinib 420 mg |
|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 19 |
AUC(0-last) is defined as area under the plasma concentration-time curve from time zero to time of last measurable concentration of ibrutinib.
| hours*nanograms per milliliter (h*ng/mL) | Ibrutinib 420 mg |
|---|---|
| Week 1: Day 1 | 3683.7 ± 3146.9 |
| Week 2: Day 1 | 4024.8 ± 4287.2 |
AUC(0-24) is defined as area under the plasma concentration-time curve from time zero to 24 hours of ibrutinib.
| hour*ng/mL | Ibrutinib 420 mg |
|---|---|
| Week 1: Day 1 | 2929.3 ± 1797.4 |
| Week 2: Day 1 | 4035.6 ± 4277.2 |
Cmax is defined as maximum observed plasma concentration of ibrutinib.
| Nanograms per milliliter (ng/mL) | Ibrutinib 420 mg |
|---|---|
| Week 1: Day 1 | 490.45 ± 366.07 |
| Week 2: Day 1 | 478.01 ± 508.08 |
Tmax is defined as time to reach the maximum observed plasma concentration of ibrutinib.
| Hours | Ibrutinib 420 mg |
|---|---|
| Week 1: Day 1 | 3.87 (1.78 to 5.75) |
| Week 2: Day 1 | 4.02 (1.75 to 5.43) |
T1/2 is defined as elimination half-life of ibrutinib.
| Hours | Ibrutinib 420 mg |
|---|---|
| Week 1: Day 1 | 4.9 (4.4 to 5.2) |
| Week 2: Day 1 | 4.4 (3.8 to 10.2) |
CL/F is defined as apparent clearance of ibrutinib.
| Milliliters per hour (mL/h) | Ibrutinib 420 mg |
|---|---|
| Week 1: Day 1 | 194211 ± 106164 |
| Week 2: Day 1 | 162457 ± 31966 |
Vd/F is defined as apparent volume of distribution of ibrutinib.
| Milliliters (mL) | Ibrutinib 420 mg |
|---|---|
| Week 1: Day 1 | 1350160 ± 748511 |
AUC(0-infinity) is defined as area under the plasma concentration-time curve from time zero to infinite time of ibrutinib.
| hour*ng/mL | Ibrutinib 420 mg |
|---|---|
| Week 1: Day 1 | 2643.8 ± 1656.2 |
| Week 2: Day 1 | 2659.2 ± 506.57 |
AUC(0-last) is defined as area under the plasma concentration-time curve from time zero to time of last measurable concentration of PCI-45227.
| h*ng/mL | Ibrutinib 420 mg |
|---|---|
| Week 1: Day 1 | 1976.9 ± 968.83 |
| Week 2: Day 1 | 2547.6 ± 999.00 |
AUC(0-24) is defined as area under the plasma concentration-time curve from time zero to 24 hours of PCI-45227.
| hour*ng/mL | Ibrutinib 420 mg |
|---|---|
| Week 1: Day 1 | 1803.0 ± 585.84 |
| Week 2: Day 1 | 2547.6 ± 999.00 |
Cmax is defined as maximum observed plasma concentration of PCI-45227.
| ng/mL | Ibrutinib 420 mg |
|---|---|
| Week 1: Day 1 | 185.37 ± 91.874 |
| Week 2: Day 1 | 203.16 ± 82.292 |
Tmax is defined as time to reach the maximum observed plasma concentration of PCI-45227.
| Hours | Ibrutinib 420 mg |
|---|---|
| Week 1: Day 1 | 4.00 (1.88 to 6.18) |
| Week 2: Day 1 | 4.02 (0.00 to 5.28) |
T1/2 is defined as elimination half-life of PCI-45227.
| Hours | Ibrutinib 420 mg |
|---|---|
| Week 1: Day 1 | 5.9 (5.2 to 6.5) |
| Week 2: Day 1 | 5.4 (5.4 to 5.4) |
CL/F is defined as apparent clearance of PCI-45227.
| mL/h | Ibrutinib 420 mg |
|---|---|
| Week 1: Day 1 | 251681 ± 68392 |
| Week 2: Day 1 | 111922 ± NA |
Vd/F is defined as apparent volume of distribution of PCI-45227.
| mL | Ibrutinib 420 mg |
|---|---|
| Week 1: Day 1 | 2148283 ± 653626 |
AUC(0-infinity) is defined as area under the plasma concentration-time curve from time zero to infinite time of PCI-45227.
| hour*ng/mL | Ibrutinib 420 mg |
|---|---|
| Week 1: Day 1 | 1766.1 ± 478.74 |
| Week 2: Day 1 | 3752.6 ± NA |
Collected over Up to 3 year 6 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ibrutinib 420 mg | 7/19 (36.8%) | 12/19 (63.2%) | 19/19 (100%) |
| Event | Ibrutinib 420 mg |
|---|---|
| PneumoniaInfections and infestations | 7/19 |
| CellulitisInfections and infestations | 3/19 |
| Renal ImpairmentRenal and urinary disorders | 2/19 |
| Immune ThrombocytopeniaBlood and lymphatic system disorders | 1/19 |
| Atrial FlutterCardiac disorders | 1/19 |
| CataractEye disorders | 1/19 |
| Gastrointestinal HaemorrhageGastrointestinal disorders | 1/19 |
| Multiple Organ Dysfunction SyndromeGeneral disorders | 1/19 |
| Liver DisorderHepatobiliary disorders | 1/19 |
| Anaphylactic ReactionImmune system disorders | 1/19 |
| Event | Ibrutinib 420 mg |
|---|---|
| StomatitisGastrointestinal disorders | 9/19 |
| CellulitisInfections and infestations | 6/19 |
| Upper Respiratory Tract InfectionInfections and infestations | 6/19 |
| Platelet Count DecreasedInvestigations | 6/19 |
| NauseaGastrointestinal disorders | 5/19 |
| PneumoniaInfections and infestations | 5/19 |
| CataractEye disorders | 4/19 |
| ConstipationGastrointestinal disorders | 4/19 |
| Oedema PeripheralGeneral disorders | 4/19 |
| HeadacheNervous system disorders | 4/19 |
| Age, Continuous(years) | Ibrutinib 420 mg |
|---|---|
| Mean | 40.5 ± 16.24 |
| Age, Customized(Participants) | Ibrutinib 420 mg |
|---|---|
| Less Than or Equal to 17 years (adolescent) | 1 |
| From 18 to 64 years | 18 |
| Sex: Female, Male(Participants) | Ibrutinib 420 mg |
|---|---|
| Female | 7 |
| Male | 12 |
| Ethnicity (NIH/OMB)(Participants) | Ibrutinib 420 mg |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 19 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Ibrutinib 420 mg |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 19 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Ibrutinib 420 mg |
|---|---|
| JAPAN | 19 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2018 to primary completion in Nov 2021, 42 months.
Results were first posted in Feb 2023, 1 year 2 months after primary completion.
Of 31 phase 3 interventional studies under Graft vs Host Disease, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 48. This study's 42 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ibrutinib